Search Results | Blood | American Society of Hematology

1-20 of 87

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy

Elise A. Chong, Cécile Alanio, Jakub Svoboda, Sunita D. Nasta, Daniel J. Landsburg, Simon F. Lacey, Marco Ruella, Siddharth Bhattacharyya, E. John Wherry, Stephen J. Schuster

Blood (2022) 139 (7): 1026–1038.

DOI: https://doi.org/10.1182/blood.2021012634

Published: 2022

Includes: Supplemental data

Journal Articles

Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions

Victor Manuel Orellana-Noia, Daniel R. Reed, Ashley Alesia McCook, Jeremy Michael Sen, Christian M. Barlow, Mary-Kate Malecek, Marcus Watkins, Brad S. Kahl, Michael A. Spinner, Ranjana Advani, Timothy J. Voorhees, Anson Snow, Natalie Sophia Grover, Amy Ayers, Jason Romancik, Yuxin Liu, Scott F. Huntington, Julio C. Chavez, Hayder Saeed, Aleksandr Lazaryan, Vikram Raghunathan, Stephen E. Spurgeon, Thomas A. Ollila, Christopher Del Prete, Adam Olszewski, Emily C. Ayers, Daniel J. Landsburg, Benjamin Echalier, Jun Lee, Manali Kamdar, Paolo F. Caimi, Timothy Fu, Jieqi Liu, Kevin A. David, Hanan Alharthy, Jennie Law, Reem Karmali, Harsh Shah, Deborah M. Stephens, Ajay Major, Alexandra E. Rojek, Sonali M. Smith, Amulya Yellala, Avyakta Kallam, Shazi Nakhoda, Nadia Khan, Mohammad Ahsan Sohail, Brian T. Hill, Odeth Barrett-Campbell, Frederick Lansigan, Jeffrey Switchenko, Jonathon Cohen, Craig A. Portell

Blood (2022) 139 (3): 413–423.

DOI: https://doi.org/10.1182/blood.2021012888

Published: 2022

Includes: Supplemental data

Journal Articles

Safety and Efficacy of Sars-Cov-2 Vaccines in Hodgkin Lymphoma Patients Receiving PD-1 Inhibitors

Jakub Svoboda, Hatcher J Ballard, Carrie I Ho, Mitchell E. Hughes, Elise A Chong, Adam Duca, Sara Prischak, Sunita Dwivedy Nasta, Marco Ruella, Daniel J Landsburg, Stefan K. Barta, James N Gerson, Stephen J. Schuster

Blood (2021) 138 (Supplement 1): 2445.

DOI: https://doi.org/10.1182/blood-2021-153122

Published: 2021

Journal Articles

Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701

Jeremy S. Abramson, Amy S. Ruppert, Sharmila Giri, Ann Hudson, Eric D. Hsi, Richard F. Little, Steven D. Gore, Anusha Vallurupalli, Daniel J Landsburg, Brad S. Kahl, Jonathan W. Friedberg, Nancy L. Bartlett, John P. Leonard

Blood (2021) 138 (Supplement 1): 523.

DOI: https://doi.org/10.1182/blood-2021-151266

Published: 2021

Journal Articles

A Multi-Institutional Retrospective Analysis of T-Cell Lymphomas with Central Nervous System Relapse

Blood (2021) 138 (Supplement 1): 1382.

DOI: https://doi.org/10.1182/blood-2021-148868

Published: 2021

Journal Articles

Bendamustine Is a Safe and Effective Regimen for Lymphodepletion before Tisagenlecleucel in Patients with Large B-Cell Lymphomas

Blood (2021) 138 (Supplement 1): 1438.

DOI: https://doi.org/10.1182/blood-2021-151766

Published: 2021

Journal Articles

The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies

Blood (2021) 138 (Supplement 1): 253.

DOI: https://doi.org/10.1182/blood-2021-153945

Published: 2021

Journal Articles

Real-World Efficacy and Safety Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Daniel J Landsburg, Matthew J. Frigault, Zhen-Huan Hu, Samantha Jaglowski, Frederick L. Locke, Christine Ho, Miguel-Angel Perales, Caron Jacobson, Brian T. Hill, Stephen Ronan Foley, Peter A. Riedell, Ranjan Tiwari, Aisha Masood, Stephen Lim, Marta Majdan, Marcelo C Pasquini, Cameron J. Turtle

Blood (2021) 138 (Supplement 1): 429.

DOI: https://doi.org/10.1182/blood-2021-146397

Published: 2021

Journal Articles

High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers

Blood (2021) 138 (Supplement 1): 455.

DOI: https://doi.org/10.1182/blood-2021-144308

Published: 2021

Journal Articles

A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results

Francisco J. Hernandez-Ilizaliturri, MD, Ian W. Flinn, MD PhD, John Kuruvilla, MD, Sarit E Assouline, MD MSc, Matthew L. Ulrickson, MD, Beth A. Christian, MD, Daniel J. Landsburg, MD, Monic Stuart, MD MPH, Henry Lowman, PhD, Nancy Levin, PhD

Blood (2020) 136 (Supplement 1): 41–42.

DOI: https://doi.org/10.1182/blood-2020-142859

Published: 2020

Journal Articles

Safety, Pharmacokinetics and Activity of CA-4948, an IRAK4 Inhibitor, for Treatment of Patients with Relapsed or Refractory Hematologic Malignancies: Results from the Phase 1 Study

Grzegorz S. Nowakowski, MD, Lori A. Leslie, MD, Anas Younes, Allison C. Rosenthal, D.O., Matthew A. Lunning, DO, FACP, Krish Patel, MD, Daniel J. Landsburg, MD, Elizabeth Martinez, PhD DHSC, MSN, Reinhard von Roemeling, MD, Christopher Lieberman, Han W. Tun, MD

Blood (2020) 136 (Supplement 1): 44–45.

DOI: https://doi.org/10.1182/blood-2020-140857

Published: 2020

Journal Articles

Everolimus Plus Itacitinib in Relapsed/Refractory Classical Hodgkin Lymphoma: Results of a Phase I/II Investigator Initiated Trial (EVITA Study)

Jakub Svoboda, MD, Stefan K. Barta, MDMRCP,MS, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, Wei-Ting Hwang, PhD, Grace Delp, Brittany Amundsen, Hatcher J. Ballard, BS, James N. Gerson, MD, Elise A. Chong, MD, Mitchell E. Hughes, PharmD, Steven A. Emanuel, Marco Ruella, MD, Stephen J. Schuster, MD

Blood (2020) 136 (Supplement 1): 20–21.

DOI: https://doi.org/10.1182/blood-2020-140507

Published: 2020

Journal Articles

CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions

Victor M. Orellana-Noia, MD, Daniel R Reed, MD, Jeremy M Sen, PharmD, BCOP, Christian Barlow, MD, Mary-Kate Malecek, MD, Brad S. Kahl, MD, Michael A Spinner, MD, Ranjana Advani, MD, Timothy J Voorhees, MD, Anson Snow, MD, Natalie S Grover, MD, Amy Ayers, MPH, Jason T. Romancik, MD, Yuxin Liu, MD, Scott F. Huntington, MD MPH, Julio C. Chavez, MD, Hayder Saeed, MD, Aleksandr Lazaryan, MDPhDMPH, Vikram Raghunathan, MD, Stephen E. Spurgeon, MD, Thomas A Ollila, MD, Christopher Del Prete, MD, Adam J Olszewski, MD, Emily C. Ayers, MD, Daniel J. Landsburg, MD, Benjamin Echalier, Jun Lee, Manali Kamdar, MD, Paolo F Caimi, MD, Timothy Fu, MD, Jieqi Liu, MD, Kevin A. David, MD, Hanan Alharthy, MD, Jennie Y. Law, MD, Reem Karmali, MDMSc, Harsh Shah, DO, Deborah M. Stephens, DO, Ajay Major, MDMBA, Alexandra E Rojek, MD, Sonali M. Smith, MD, Amulya Yellala, MBBS, Avyakta Kallam, MD, Shazia Nakhoda, MD, Nadia Khan, MD, Jonathon B. Cohen, MDMS, Craig A. Portell, MD

Blood (2020) 136 (Supplement 1): 27–28.

DOI: https://doi.org/10.1182/blood-2020-134798

Published: 2020

Journal Articles

Outcomes of Patients with Limited-Stage Plasmablastic Lymphoma

Blood (2020) 136 (Supplement 1): 15–16.

DOI: https://doi.org/10.1182/blood-2020-138536

Published: 2020

Journal Articles

Anti-CD19 CAR-T for Treatment of Double Expressor and Double Hit Large B-Cell Lymphomas: A Single Institution Real-World Analysis

Elise A. Chong, MD, Emeline R. Chong, Daniel J. Landsburg, MD, James N. Gerson, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, Stefan K. Barta, MDMRCP,MS, Alfred L. Garfall, MD, Elizabeth Weber, BSN, RN, Marco Ruella, MD, Noelle V. Frey, MD, David L. Porter, MD, Stephen J. Schuster, MD

Blood (2020) 136 (Supplement 1): 19–20.

DOI: https://doi.org/10.1182/blood-2020-143348

Published: 2020

Journal Articles

Patterns and Risk of CNS Recurrence after R-EPOCH Treatment for Double/Triple Hit Lymphoma

Blood (2020) 136 (Supplement 1): 24–25.

DOI: https://doi.org/10.1182/blood-2020-142299

Published: 2020

Journal Articles

A Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a Novel IRAK4 Inhibitor CA-4948 in Combination with Ibrutinib, in Patients with Relapsed or Refractory Hematologic Malignancies

Grzegorz S. Nowakowski, MD, Lori A. Leslie, MD, Erel Joffe, MD MSc, Allison C. Rosenthal, D.O., Matthew A. Lunning, DO, FACP, Krish Patel, MD, Monica Mead, MD BS, Daniel J. Landsburg, MD, Timothy S. Fenske, MD, Radhakrishnan Ramchandren, Praveen Ramakrishnan Geethakumari, MD MS, Alan Skarbnik, MD, Elizabeth Martinez, PhD DHSC, MSN, Christopher Lieberman, Reinhard von Roemeling, MD, Han W. Tun, MD

Blood (2020) 136 (Supplement 1): 49–50.

DOI: https://doi.org/10.1182/blood-2020-140884

Published: 2020

Journal Articles

Radiation-Based Approaches As an Alternative to Stem Cell Transplant for Relapsed/Refractory Classical Hodgkin Lymphoma: A Multicenter Retrospective Analysis

Blood (2020) 136 (Supplement 1): 31–32.

DOI: https://doi.org/10.1182/blood-2020-142089

Published: 2020

Journal Articles

A Multi-Center Analysis of the Impact of Dose Level of R-EPOCH on Outcomes of Patients with Double/Triple-Hit B-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 32–34.

DOI: https://doi.org/10.1182/blood-2020-142958

Published: 2020

Journal Articles

A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0404

Jonathon B. Cohen, MDMS, Craig A. Portell, MD, Mehdi Hamadani, MD, Opeyemi Jegede, PhD, Catherine Diefenbach, MD, Kevin A. David, MD, Christopher D. Fletcher, MD, Daniel J. Landsburg, MD, Brad S. Kahl, MD

Blood (2019) 134 (Supplement_1): 1541.

DOI: https://doi.org/10.1182/blood-2019-127494

Published: 2019

2 3 4 5

NARROW

Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy

Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions

Safety and Efficacy of Sars-Cov-2 Vaccines in Hodgkin Lymphoma Patients Receiving PD-1 Inhibitors

Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701

A Multi-Institutional Retrospective Analysis of T-Cell Lymphomas with Central Nervous System Relapse

Bendamustine Is a Safe and Effective Regimen for Lymphodepletion before Tisagenlecleucel in Patients with Large B-Cell Lymphomas

The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies

Real-World Efficacy and Safety Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers

A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results

Safety, Pharmacokinetics and Activity of CA-4948, an IRAK4 Inhibitor, for Treatment of Patients with Relapsed or Refractory Hematologic Malignancies: Results from the Phase 1 Study

Everolimus Plus Itacitinib in Relapsed/Refractory Classical Hodgkin Lymphoma: Results of a Phase I/II Investigator Initiated Trial (EVITA Study)

CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions

Outcomes of Patients with Limited-Stage Plasmablastic Lymphoma

Anti-CD19 CAR-T for Treatment of Double Expressor and Double Hit Large B-Cell Lymphomas: A Single Institution Real-World Analysis

Patterns and Risk of CNS Recurrence after R-EPOCH Treatment for Double/Triple Hit Lymphoma

A Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a Novel IRAK4 Inhibitor CA-4948 in Combination with Ibrutinib, in Patients with Relapsed or Refractory Hematologic Malignancies

Radiation-Based Approaches As an Alternative to Stem Cell Transplant for Relapsed/Refractory Classical Hodgkin Lymphoma: A Multicenter Retrospective Analysis

A Multi-Center Analysis of the Impact of Dose Level of R-EPOCH on Outcomes of Patients with Double/Triple-Hit B-Cell Lymphoma

A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0404

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only